CHARIOT: A phase I dose escalation study combining ATR inhibitor Berzosertib with chemoradiotherapy in oesophageal cancer using time to event continual reassessment (TiTE-CRM) method: Results from A1 cohort (combination with palliative RT)
Authors
Mukherjee, S.Lord, S.
Harman, R.
McIntosh, D.
Ooms, A.
Parkes, M.
Radhakrishna, Ganesh
Shaw, P. H.
Hawkins, M. A.
Affiliation
Oncology Department, Oxford University Hospital NHS Foundation Trust, Oxford, UKIssue Date
2022
Metadata
Show full item recordCitation
Mukherjee S, Lord S, Harman R, McIntosh D, Ooms A, Parkes M, et al. CHARIOT: A phase I dose escalation study combining ATR inhibitor Berzosertib with chemoradiotherapy in oesophageal cancer using time to event continual reassessment (TiTE-CRM) method: Results from A1 cohort (combination with palliative RT). Annals of Oncology. 2022 Sep;33(7):S1120-S. PubMed PMID: WOS:000866211601512.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.07.1369Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.07.1369Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.07.1369